



(51) International Patent Classification:

A01N 43/00 (2006.01) A61K 31/554 (2006.01)  
A61K 31/553 (2006.01)

(21) International Application Number:

PCT/US2008/063374

(22) International Filing Date:

12 May 2008 (12.05.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/938,089 15 May 2007 (15.05.2007) US

(71) Applicant (for all designated States except US): OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LIU, Yongge [US/US]; c/o Otsuka Maryland Medicinal Laboratories, Inc., 9900 Medical Center Drive, Rockville, Maryland 20850 (US). KAMBAYASHI, Junichi [JP/US]; c/o Otsuka Maryland Medicinal Laboratories, Inc., 9900 Medical Center Drive, Rockville, Maryland 20850 (US).

(74) Agents: SYLVESTER, Brett, S. et al.; Sughrue Mion, PLLC, 2100 Pennsylvania Ave., N.W., Suite 800, Washington, DC 20037-3213 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE CARDIOTOXICITY AND/OR IMPROVE SURVIVAL

Figure 1



Dox: doxorubicin. Tol: tolvaptan. Veh: vehicle.

Kaplan-Meier Survival Analysis of tol vaptan-treated rats.

(57) Abstract: The present invention relates to methods of reducing cardiotoxicity and/or improving survival from treatment with anthracycline agents comprising administering a therapeutically effective amount of a composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof as an active ingredient, administered simultaneously or prior to the anthracycline administration.



---

**(88) Date of publication of the international search report:**  
21 January 2010